NextPlat Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXPL research report →
Price Chart
About the company
NextPlat Corp, along with its subsidiaries, specializes in providing advanced mobile satellite services (MSS). These offerings encompass satellite-enabled voice and data communication, comprehensive personnel and asset tracking, machine-to-machine (M2M) solutions, and Internet of Things (IoT) connectivity, serving clients across the United States and internationally. Their product portfolio features satellite communication devices that empower users to make voice calls, exchange text messages and emails, and transmit GPS coordinates from virtually any location.
- CEO
- David Phipps
- IPO
- 1999
- Employees
- 126
- HQ
- Hallandale Beach, FL, US
Get TickerSpark's AI analysis on NXPL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.97M
- P/E
- -2.36
- Fwd P/E
- 11.33
- PEG
- 0.12
- P/S
- 0.46
- P/B
- 1.32
- EV/EBITDA
- -1.69
- Div Yield
- 0.00%
- Gross Margin
- 24.85%
- Op Margin
- -12.11%
- Net Margin
- -18.66%
- ROE
- -51.01%
- ROIC
- -31.25%
Latest fiscal year · YoY change
- Revenue
- $54.32M-17.0%
- Gross Profit
- $10.91M-32.8%
- Op Income
- $-8,750,000
- Net Income
- $-11,712,000+16.5%
- EPS
- $-4.50+33.8%
- OCF Growth
- -12.2%
- FCF Growth
- -9.7%
- 52W High
- $9.94
- 52W Low
- $3.38
- 50D MA
- $8.63
- 200D MA
- $6.89
- Beta
- 1.91
- RSI (14)
- 43
- Avg Volume
- 26.54K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NextPlat said Q3 showed sharply improved profitability, driven by a bigger mix of higher-margin 340B contract pharmacy business even as retail prescription pressure and a facility closure weighed on revenue.· November 12, 2026
- Total Q3 net revenue was $10.5 million, down from $13.8 million a year ago, but gross profit improved to $3.7 million from $2.7 million.
- Consolidated gross margin rose to 35% from nearly 20% year over year, while operating loss narrowed to $0.8 million from $2.2 million.
- Healthcare revenue shifted toward higher-margin contract services: pharmacy contract revenue was $2.4 million versus $0.6 million last year, and quarterly contracted pharmacy revenue increased nearly 300% year over year.
- Cash ended the quarter at $11.2 million, with no meaningful debt; Scott's Pharmacy was bought for $1.5 million in cash and is expected to add about $1.2 million in quarterly revenue and $150,000 in net profit in Q4.
- Management highlighted ongoing expansion through Florida pharmacy acquisitions, the new Jacksonville location, a planned healthcare e-commerce launch, and continued international e-commerce growth, including Decathlon and other marketplaces.
Q3 2026 total net revenues were $10.5 million versus $13.8 million in Q3 2025. Healthcare revenue was $6.7 million versus $10.1 million, and pharmacy contract revenue was $2.4 million versus $0.6 million a year ago. Consolidated gross profit was $3.7 million versus $2.7 million, with gross margin at 35% versus nearly 20% a year ago; healthcare gross margin was a little over 41%, up from 18% a year earlier but down about 5 percentage points sequentially. Operating expenses were $4.5 million versus $5.0 million, and operating loss improved to $0.8 million from $2.2 million. Cash was $11.2 million at quarter-end, working capital was $13.5 million, and the company said it has no meaningful debt. For Q4, management said Scott's Pharmacy is expected to contribute about $1.2 million in quarterly revenue and $150,000 in net profit, and that the new healthcare e-commerce site is now expected to go live this month.
David Phipps framed the quarter as evidence that the turnaround is working, emphasizing stronger margins, lower operating losses, and a shift toward higher-margin contracted healthcare services. He said the company is pursuing a diversified model that combines retail pharmacy with 340B, institutional, specialty, and government services, while selectively adding profitable acquisitions such as Scott's Pharmacy. His tone was constructive and confident, but he acknowledged continued volatility in the retail healthcare business and said the company still has work to do on top-line growth and profitability.
Amanda Ferrio said Q3 continued to show year-over-year improvement in gross margin, operating expenses, and operating loss, largely due to the shift toward contracted healthcare services. She noted consolidated gross margin of 35%, gross profit of $3.7 million, operating expenses of $4.5 million, and an operating loss of $0.8 million, plus cash of $11.2 million and working capital of $13.5 million. She also pointed out that Scott's was an all-cash acquisition for $1.5 million and that the company raised over $140,000 in net proceeds from ATM share sales during Q4, while maintaining no meaningful debt.
The most notable Q&A centered on growth plans after the Pensacola acquisition, the expected contribution of the new healthcare e-commerce site, and the status of an ongoing lawsuit. Management said it will continue looking at pharmacy opportunities inside and outside Florida, but will only pursue deals that meet strict revenue, margin, and profitability requirements. On the e-commerce site, management described it as a new revenue stream and said it would provide updates in coming quarters, while on the lawsuit it said the situation remains largely unchanged and that counsel and the insurance company are actively working to resolve it.
The bullish case is that the company is showing real margin improvement and much better operating leverage as it shifts toward contracted healthcare services. Management also pointed to growth catalysts in Scott's Pharmacy, Jacksonville, new 340B contracts, a coming healthcare e-commerce launch, and broader international e-commerce expansion.
The main risks are that retail pharmacy volumes remain under pressure from reimbursement rates, payer mix, and customers bringing prescriptions in-house, and that a facility closure hurt sequential profitability. Management also said healthcare results can be volatile, the new e-commerce site has been delayed slightly, and the lawsuit is still ongoing and generating expenses.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.8%
- Shares Outstanding
- 2.71M
- Float Shares
- 1.89M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 240.92K | ▼ 972 |
| Eversource Wealth Advisors, LLC | 58.07K | 0 |
| Vanguard Capital Management LLC | 21.42K | 0 |
| Geode Capital Management, LLC | 20.53K | ▼ 1.46K |
| Renaissance Technologies LLC | 18.98K | ▲ 18.98K |
| Citadel Advisors LLC | 18.58K | ▲ 18.58K |
| Hrt Financial LP | 11.98K | ▲ 11.98K |
| Vanguard Fiduciary Trust Co | 9.06K | 0 |
| Ubs Group AG | 2.97K | ▲ 2.97K |
| Tower Research Capital LLC (Trc) | 642 | ▼ 1.93K |
| Vanguard Global Advisers, LLC | 264 | 0 |
| Caitong International Asset Management Co., Ltd | 9 | ▲ 9 |
Held by 22 ETFs
Biggest fund positions in NXPL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 26 | Bedwell Robert Phillip Jr. | other | 1,250 |
| Oct 14, 26 | Ferrio Amanda | other | 3,000 |
| Oct 14, 26 | Phipps David | other | 6,000 |
| Sep 30, 26 | Armas Anthony | other | 661 |
| Sep 30, 26 | Barreto Rodney | other | 1,323 |
| Sep 30, 26 | ELLENOFF DOUGLAS | other | 1,323 |
| Jun 30, 26 | Barreto Rodney | other | 1,886 |
| Jun 30, 26 | Armas Anthony | other | 943 |
| Jun 30, 26 | ELLENOFF DOUGLAS | other | 1,886 |
| Apr 6, 26 | Armas Anthony | other | 12,162 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NXPL coverage
Recent articles, reports, and earnings notes.
No research on NXPL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXPL report →NextPlat Announces PharmcoRx Agreement with MedSure Systems to Support Medication Adherence for Retail Medicare Patients in South Florida
prnewswire.com · Nov 19
NextPlat Corp. (NXPL) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
NextPlat Reports 3Q Results with Nearly 35% Improvement in Year-Over-Year Gross Profit, Consolidated Quarterly Gross Margins of 35% & Approximately 66% Reduction in Net Loss
prnewswire.com · Nov 12
NextPlat to Release Third Quarter 2026 Results on Thursday, November 12, 2026
prnewswire.com · Nov 6
Reviewing Kroger (NYSE:KR) & NextPlat (NASDAQ:NXPL)
defenseworld.net · Nov 6
NextPlat's PharmcoRx to Launch Automated Point-of-Care Prescription Dispensing Supporting Improved Patient Adherence and Pharmacy Growth
prnewswire.com · Oct 22
NextPlat Opens New Jacksonville Pharmacy Location to Offer High-Value Services for Patients and Local Healthcare Providers
prnewswire.com · Oct 13
NextPlat Completes Pensacola-Area Acquisition of Profitable Pharmacy, Accelerating Continued Healthcare Growth and Profitability
prnewswire.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.